STOCK TITAN

Venrock funds report 5.8% ORIC (ORIC) ownership stake in latest filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

ORIC Pharmaceuticals’ institutional holders led by Venrock Healthcare Capital Partners report a 5.8% beneficial stake in the company’s common stock. The group, including several Venrock funds and individuals Nimish Shah and Bong Koh, collectively owns 5,676,230 ORIC common shares as of December 31, 2025.

The ownership is spread across VHCP III, VHCP Co-Investment III, and VHCP EG funds, with control entities VHCP Management III and VHCP Management EG. The percentage is calculated using 97,389,279 shares outstanding as of November 5, 2025, from ORIC’s Form 10-Q, and the group certifies the holdings are not for changing or influencing control.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Venrock Healthcare Capital Partners III, L.P.
Signature:/s/ Sherman G. Souther
Name/Title:By VHCP Management III, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
Date:02/17/2026
VHCP Co-Investment Holdings III, LLC
Signature:/s/ Sherman G. Souther
Name/Title:By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
Date:02/17/2026
Venrock Healthcare Capital Partners EG, L.P.
Signature:/s/ Sherman G. Souther
Name/Title:By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
Date:02/17/2026
VHCP Management III, LLC
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Authorized Signatory
Date:02/17/2026
VHCP Management EG, LLC
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Authorized Signatory
Date:02/17/2026
Nimish Shah
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Attorney-in-fact
Date:02/17/2026
Bong Y. Koh
Signature:/s/ Sherman G. Souther
Name/Title:By Sherman G. Souther, Attorney-in-fact
Date:02/17/2026
Exhibit Information

Exhibit 24.1 Power of Attorney for Nimish Shah (incorporated by reference to Exhibit 24.1 to Schedule 13G filed on May 30, 2025) Exhibit 24.2 Power of Attorney for Bong Koh (incorporated by reference to Exhibit 24.2 to Schedule 13G filed on May 30, 2025) Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to Schedule 13G filed on May 30, 2025)

FAQ

What percentage of ORIC (ORIC) does the Venrock group report owning in this Schedule 13G/A?

The Venrock-related reporting persons collectively report beneficial ownership of 5.8% of ORIC Pharmaceuticals’ common stock. This percentage is based on 97,389,279 shares outstanding as of November 5, 2025, as disclosed in ORIC’s Form 10-Q.

How many ORIC (ORIC) shares are beneficially owned by the Venrock group?

The reporting persons collectively beneficially own 5,676,230 shares of ORIC Pharmaceuticals common stock. These shares are held across VHCP III, VHCP Co-Investment III, and VHCP EG funds, with shared voting and dispositive power reported for the entire amount.

Which entities and individuals are reporting persons in ORIC (ORIC) this Schedule 13G/A?

Reporting persons include Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, VHCP EG, VHCP Management III, LLC, VHCP Management EG, LLC, and individuals Nimish Shah and Bong Y. Koh, who are voting members of the management entities.

As of what date is the ORIC (ORIC) ownership information in this Schedule 13G/A reported?

The beneficial ownership information is reported as of December 31, 2025. The ownership percentages use a denominator of 97,389,279 ORIC common shares outstanding as of November 5, 2025, taken from the company’s Form 10-Q filed on November 13, 2025.

How are the 5,676,230 ORIC (ORIC) shares allocated among the Venrock funds?

The ownership consists of 1,080,110 shares held by VHCP III, 108,023 shares held by VHCP Co-Investment III, and 4,488,097 shares held by VHCP EG. Management entities VHCP Management III and VHCP Management EG exercise control over the respective funds’ holdings.

Does the Venrock group seek to influence control of ORIC (ORIC) according to this filing?

The reporting persons certify the ORIC shares were not acquired and are not held for changing or influencing control of the issuer. They also state the holdings are not in connection with any transaction having that purpose, aside from activities related to director nominations under applicable rules.
Oric Pharmaceuticals, Inc.

NASDAQ:ORIC

ORIC Rankings

ORIC Latest News

ORIC Latest SEC Filings

ORIC Stock Data

1.10B
87.10M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO